Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 7067633
Targeting cellular entry, cell survival, and pathogenicity by dynein light chain 1/PIN in human cells
granted -
US 7067256
Ribozyme mediated inactivation of the androgen receptor
granted -
US 7067653
Porphyrin Based neuton capture agents for cancer therapy
granted -
US 7063847
Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
granted -
US 7060689
Methods and compositions for delivery and retention of active agents to lymph nodes
granted -
US 7061237
Remote NMR/MRI detection of laser polarized gases
granted -
US 7060688
Products and methods for controlling the suppression of the neoplastic phenotype
granted -
US 7060466
Methods of producing hyaluronic acid using a recombinant hyaluronan synthase gene
granted -
US 7060686
Anti-inflammatory compounds derived from Pseudopterogorgia elisabethae
granted -
US 7060733
Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
granted -
US 7060442
Modulators on Nod2 signaling
granted -
US 7056945
Selective inhibition of neuronal nitric oxide synthase
granted -
US 7056532
Compositions for delivery of biological agents and methods for the preparation thereof
granted -
US 7056509
Antibody methods for selectively inhibiting VEGF
granted -
US 7056901
Microgel particles for the delivery of bioactive materials
granted -
US 7056897
Inducible expression vectors and methods of use thereof
granted -
US 7056741
Surface transfection and expression procedure
granted -
US 7056514
Partial peptide mimetics and methods
granted -
US 7056501
Recombinant neospora antigens and their uses
granted -
US 7056506
Methods for detecting and inhibiting angiogenesis
granted -
US 7056513
Telomerase
granted -
US 7056503
Enclosures housing cell-coated supports for treating tumors
granted -
US 7052674
Prokineticin polypeptides, related compositions and methods
granted -
US 7052829
Prevascularized constructs for implantation to provide blood perfusion
granted -
US 7052856
NELL-1 enhanced bone mineralization
granted -
US 7053263
Mouse models of human prostate cancer progression
granted -
US 7052676
Methods for inhibition of HIV replication using a small molecule inhibitor
granted -
US 7053119
Methods for identifying and using IKK inhibitors
granted -
US 7049066
Diagnosis and treatment of myocardial failure
expired -
US 7045326
Mono- and diacylglycerol acyltransferases and methods of use thereof
expired -
US 7045283
Methods of high-throughput screening for internalizing antibodies
expired -
US 7045293
Alteration of sequence of a target molecule
expired -
US 7045337
In vivo incorporation of unnatural amino acids
expired -
US 7041806
Netrin receptors
expired -
US 7041784
Apoptotic compounds
expired -
US 7041462
Conformational and topological protein regulation
expired -
US 7041443
Porcine reproductive and respiratory syndrome virus and methods of use
expired -
US 7041481
Chemical amplification based on fluid partitioning
expired -
US 7037583
Functionalized zirconium oxide particles
expired -
US 7037901
Radiosensitization by indolocarbazole derivatives
expired -
US 7037533
Functional agent for decomposing nicotine and method of preparing the same
expired -
US 7037501
Myostatin immnoconjugate
expired -
US 7033603
Drug releasing biodegradable fiber for delivery of therapeutics
expired -
US 7033750
Recombinant P53 adenovirus methods and compositions
expired -
US 7034014
Phosphonate compounds
expired -
US 7030232
E25A protein, methods for producing and use thereof
expired -
US 7029652
Method of treating tumors
expired -
US 7029696
Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory